Abnormally high levels of lung-injury biomarkers in the blood after COVID-19 infection may flag patients at risk for ongoing lung disease, an Imperial College London–led study suggests.
Blood-based biomarker testing might identify patients at increased risk for chronic lung disease following hospitalization for COVID-19.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results